Figure 1
The disease-free survival rate was analyzed by the Kaplan-Meier method. In patients with or without adjuvant sorafenib, it was 100% versus 37.5% (p = 0.034) at 6 months, 66.7% versus 9.4% (p = 0.026) at 12 months, and 66.7% versus 0.0% (p = 0.011) at 18 months, respectively. Adjuvant sorafenib could significantly improve disease-free survival in patients beyond the Milan criteria after orthopedic liver transplantation.